You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Accurate Prostate Cancer Diagnosis for Active Surveillance Patients Using a Novel

    SBC: ProDevice Medical Supplies and Equipment LLC            Topic: NCI

    Project Abstract Active surveillance (AS) is becoming more accepted as a reasonable treatment option for men with low-risk prostate cancer (i.e. Gleason score 6, clinical stage T2a, PSA lt 10). Many AS protocols at major institutions call for a prostate saturation biopsy after initial diagnosis to confirm that the patient has no areas of higher-risk prostate cancer. For most patients who underwent ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Advanced Assessment to Accelerate Diagnostic Skill Acquisition

    SBC: Parallel Consulting, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Current approaches to medical education produce new physicians with insufficient clinical competency to practice effectively with limited supervision, which has serious implications for patient outcomes during hospitaloff hours. Up to 70% of patients admitted to a hospital are admitted on nights or weekends, when staffing is low and residents may be in charge o ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A Genes-to-Molecules Platform for Expanding Natural Product Diversity

    SBC: Lassogen, Inc.            Topic: NCCIH

    Project Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. A molecularly targeted pre- and post-exposure vaccine for anthrax

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant We have shown that immunization of rabbits with multiple antigenic peptides MAPs displaying sequence from domain of protective antigen PA elicit antibodies specific for a linear determinant within the loop of PA that mediate potent neutralization of lethal toxin LeTx in vitro We have now shown in two separate large studies that antibodies aga ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Amplification-free megabase target-enrichment for next-generation sequencing

    SBC: Mission Bio, Inc.            Topic: NHGRI

    DESCRIPTION (provided by applicant): Target enrichment for next-generation sequencing enables researchers to reduce the burden of sequence data analysis, obtain higher levels of statistical significance by examining more genomes and increase sequencing coverage depth. The goal of this STTR proposal is to develop and commercialize a novel technology capable of amplification-free megabase target seq ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    DESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. An augmented reality platform to reduce post-operative and chronic opioid use in pediatric cancer

    SBC: ALTALITY, INC.            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT Pediatric opioid use is a public health crisis. In children, prescription opioids are the primary source of non- medical abuse as well as opioid-associated hospitalizations and deaths. Early opioid use in childhood is a known “gateway” to adulthood dependence and substance abuse disorders. Despite years of research, opioids remain the most commonly prescribed pain medi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. An innovative in situ cell reprogramming technology for cancer treatment

    SBC: QURGEN, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): We invented an innovative protein induced Pluripotent Stem Cells (piPSCs) technology that generates piPSCs from normal fibroblast and cancer cells within 1-week with 90 4% conversion efficiency. Such high conversion efficiency enables us to pioneer an in situ cell reprogramming technology within the cancers of cancer-bearing animals. Instead of generating iPSCs ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel, Field-Deployable, Biomimetic Narcotics Detector for the Identification of Fentanyl and Other Synthetic Opioids

    SBC: SEACOAST SCIENCE, INC.            Topic: NIDA

    AbstractThe alarming scope of the rapidly growing opioid epidemic has commanded the nation’s attention. The White House’s Council of Economic Advisers estimates that in 2015, the economic cost of the opioid crisis was over $504.0 billion (2.8% of GDP); and it is only expected to continue rising. Today, 1 in 5 fatalities amongst young adults is opioid related; with half a million fatal overdose ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. A novel role for Reelin therapeutics in inflammatory bowel disease

    SBC: REELIN THERAPEUTICS, INC.            Topic: 300

    Abstract Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely understood. Although specific genetic factors may increase risk, most IBD cannot be readily explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated. Once IBD is established, chronic inflammation is a central hallmark and also a major target for therapy. Both forms ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government